KR102937044B1 - Kdm5 억제 활성을 갖는 화합물 및 이의 약학적 용도 - Google Patents
Kdm5 억제 활성을 갖는 화합물 및 이의 약학적 용도Info
- Publication number
- KR102937044B1 KR102937044B1 KR1020227037880A KR20227037880A KR102937044B1 KR 102937044 B1 KR102937044 B1 KR 102937044B1 KR 1020227037880 A KR1020227037880 A KR 1020227037880A KR 20227037880 A KR20227037880 A KR 20227037880A KR 102937044 B1 KR102937044 B1 KR 102937044B1
- Authority
- KR
- South Korea
- Prior art keywords
- azabicyclo
- mmol
- alkyl
- compound
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020267006670A KR20260046494A (ko) | 2020-05-07 | 2021-05-06 | Kdm5 억제 활성을 갖는 화합물 및 이의 약학적 용도 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/088925 | 2020-05-07 | ||
| CN2020088925 | 2020-05-07 | ||
| PCT/CN2021/091843 WO2021223699A1 (en) | 2020-05-07 | 2021-05-06 | 3-azabicyclo(3.1.0)hexane derivatives having kdm5 inhibitory activity and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020267006670A Division KR20260046494A (ko) | 2020-05-07 | 2021-05-06 | Kdm5 억제 활성을 갖는 화합물 및 이의 약학적 용도 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20230007352A KR20230007352A (ko) | 2023-01-12 |
| KR102937044B1 true KR102937044B1 (ko) | 2026-03-09 |
Family
ID=76159223
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227037880A Active KR102937044B1 (ko) | 2020-05-07 | 2021-05-06 | Kdm5 억제 활성을 갖는 화합물 및 이의 약학적 용도 |
| KR1020267006670A Pending KR20260046494A (ko) | 2020-05-07 | 2021-05-06 | Kdm5 억제 활성을 갖는 화합물 및 이의 약학적 용도 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020267006670A Pending KR20260046494A (ko) | 2020-05-07 | 2021-05-06 | Kdm5 억제 활성을 갖는 화합물 및 이의 약학적 용도 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11691968B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4471027A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7643466B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102937044B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN115461338B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021268223C1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022022005A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3181604A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3037418T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL297900B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022013692A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI895412B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021223699A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3999183A4 (en) * | 2019-07-17 | 2023-11-15 | Ono Pharmaceutical Co., Ltd. | COMPOUNDS HAVING KDM5 INHIBITANT ACTION AND THEIR PHARMACEUTICAL USES |
| AU2021268223C1 (en) | 2020-05-07 | 2026-07-09 | Ono Pharmaceutical Co., Ltd. | Compound having KDM5 inhibitory activity and pharmaceutical use thereof |
| JP2023070165A (ja) * | 2021-11-05 | 2023-05-18 | 小野薬品工業株式会社 | アザビシクロ環化合物の結晶 |
| JP7743829B2 (ja) * | 2021-11-05 | 2025-09-25 | 小野薬品工業株式会社 | Kdm5阻害作用を有する化合物を含有する医薬組成物 |
| TW202612686A (zh) * | 2024-05-17 | 2026-04-01 | 日商小野藥品工業股份有限公司 | 失智症之行動及心理症狀之預防、進展抑制及/或治療劑 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016057924A1 (en) | 2014-10-10 | 2016-04-14 | Genentech, Inc. | Pyrrolidine amide compounds as histone demethylase inhibitors |
| WO2021010492A1 (en) | 2019-07-17 | 2021-01-21 | Ono Pharmaceutical Co., Ltd. | Compound having kdm5 inhibitory activity and pharmaceutical use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI244481B (en) | 1998-12-23 | 2005-12-01 | Pfizer | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy |
| GB0311859D0 (en) | 2003-05-22 | 2003-06-25 | Merck Sharp & Dohme | Therapeutic agents |
| EP1765379A4 (en) | 2004-06-17 | 2009-05-27 | Transform Pharmaceuticals Inc | PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS AND RELEVANT USE METHOD |
| JP2008524331A (ja) | 2004-12-21 | 2008-07-10 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
| WO2009047161A1 (en) | 2007-10-09 | 2009-04-16 | F. Hoffmann-La Roche Ag | Chiral cis-imidazolines |
| CN108341819B (zh) | 2017-01-22 | 2021-06-15 | 南京药捷安康生物科技有限公司 | 磷酸二酯酶抑制剂及其用途 |
| AU2021268223C1 (en) | 2020-05-07 | 2026-07-09 | Ono Pharmaceutical Co., Ltd. | Compound having KDM5 inhibitory activity and pharmaceutical use thereof |
-
2021
- 2021-05-06 AU AU2021268223A patent/AU2021268223C1/en active Active
- 2021-05-06 CN CN202180032139.2A patent/CN115461338B/zh active Active
- 2021-05-06 IL IL297900A patent/IL297900B2/en unknown
- 2021-05-06 BR BR112022022005A patent/BR112022022005A2/pt unknown
- 2021-05-06 EP EP24182835.9A patent/EP4471027A1/en active Pending
- 2021-05-06 ES ES21728166T patent/ES3037418T3/es active Active
- 2021-05-06 KR KR1020227037880A patent/KR102937044B1/ko active Active
- 2021-05-06 EP EP21728166.6A patent/EP4146645B1/en active Active
- 2021-05-06 TW TW110116409A patent/TWI895412B/zh active
- 2021-05-06 JP JP2022567355A patent/JP7643466B2/ja active Active
- 2021-05-06 KR KR1020267006670A patent/KR20260046494A/ko active Pending
- 2021-05-06 CA CA3181604A patent/CA3181604A1/en active Pending
- 2021-05-06 WO PCT/CN2021/091843 patent/WO2021223699A1/en not_active Ceased
- 2021-05-06 MX MX2022013692A patent/MX2022013692A/es unknown
-
2022
- 2022-10-24 US US17/971,844 patent/US11691968B2/en active Active
-
2023
- 2023-05-05 US US18/144,030 patent/US12269817B2/en active Active
-
2024
- 2024-10-02 JP JP2024173464A patent/JP7643632B2/ja active Active
-
2025
- 2025-02-26 JP JP2025029239A patent/JP2025081677A/ja not_active Withdrawn
- 2025-02-28 US US19/067,084 patent/US20250214984A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016057924A1 (en) | 2014-10-10 | 2016-04-14 | Genentech, Inc. | Pyrrolidine amide compounds as histone demethylase inhibitors |
| WO2021010492A1 (en) | 2019-07-17 | 2021-01-21 | Ono Pharmaceutical Co., Ltd. | Compound having kdm5 inhibitory activity and pharmaceutical use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022022005A2 (pt) | 2022-12-13 |
| CN115461338B (zh) | 2024-02-20 |
| US12269817B2 (en) | 2025-04-08 |
| JP7643466B2 (ja) | 2025-03-11 |
| US20230109293A1 (en) | 2023-04-06 |
| US20250214984A1 (en) | 2025-07-03 |
| CN115461338A (zh) | 2022-12-09 |
| JP7643632B2 (ja) | 2025-03-11 |
| MX2022013692A (es) | 2022-11-30 |
| KR20260046494A (ko) | 2026-04-07 |
| JP2025081677A (ja) | 2025-05-27 |
| EP4471027A1 (en) | 2024-12-04 |
| JP2024177345A (ja) | 2024-12-19 |
| KR20230007352A (ko) | 2023-01-12 |
| EP4146645B1 (en) | 2025-06-25 |
| IL297900B2 (en) | 2026-04-01 |
| US20230271952A1 (en) | 2023-08-31 |
| EP4146645A1 (en) | 2023-03-15 |
| ES3037418T3 (en) | 2025-10-01 |
| AU2021268223C1 (en) | 2026-07-09 |
| IL297900A (en) | 2023-01-01 |
| NZ793960A (en) | 2025-12-19 |
| JP2023524547A (ja) | 2023-06-12 |
| AU2021268223B2 (en) | 2025-10-09 |
| WO2021223699A1 (en) | 2021-11-11 |
| CA3181604A1 (en) | 2021-11-11 |
| TW202200571A (zh) | 2022-01-01 |
| AU2021268223A1 (en) | 2022-12-08 |
| US11691968B2 (en) | 2023-07-04 |
| IL297900B1 (en) | 2025-12-01 |
| TWI895412B (zh) | 2025-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12269817B2 (en) | Compound having KDM5 inhibitory activity and pharmaceutical use thereof | |
| JP7786517B2 (ja) | Kdm5阻害活性を有する化合物およびその医薬用途 | |
| JP7647552B2 (ja) | Ep2アンタゴニスト | |
| JP2016514709A (ja) | ヤヌスキナーゼ阻害剤としてのジェミナル置換シアノエチルピラゾロピリドン | |
| WO2022138793A1 (ja) | Ep2受容体拮抗薬と免疫チェックポイント阻害薬および/またはep4受容体拮抗薬との組み合わせ | |
| JP2024128038A (ja) | Abhd6アンタゴニスト | |
| JP6922712B2 (ja) | 医薬用途 | |
| RU2840256C1 (ru) | Соединение, обладающее ингибирующей активностью в отношении kdm5, и его фармацевтическое применение | |
| JP7743829B2 (ja) | Kdm5阻害作用を有する化合物を含有する医薬組成物 | |
| KR20230065914A (ko) | Kdm5 억제 활성을 갖는 화합물을 포함하는 약학 조성물 | |
| TWI907744B (zh) | 包含具有kdm5抑制活性之化合物之醫藥組合物 | |
| HK40083699A (en) | 3-azabicyclo(3.1.0)hexane derivatives having kdm5 inhibitory activity and use thereof | |
| HK40083699B (en) | 3-azabicyclo(3.1.0)hexane derivatives having kdm5 inhibitory activity and use thereof | |
| RU2857204C2 (ru) | Антагонист abhd6 | |
| JP2022101520A (ja) | Ep2アンタゴニストを含有する医薬組成物 | |
| JP2024052624A (ja) | Abhd6アンタゴニストを含有する医薬組成物 | |
| HK40067217A (en) | Ep2 antagonist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R15-X000 | Change to inventor requested |
St.27 status event code: A-3-3-R10-R15-oth-X000 |
|
| R16-X000 | Change to inventor recorded |
St.27 status event code: A-3-3-R10-R16-oth-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| A16 | Divisional, continuation or continuation in part application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |